Ligand Pharma (LGND) shares resume trading; shares up ~8%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Ligand Pharma (LGND) to resume trading at 9:45AM after FDA approval
November 19, 2012 9:20 AM ESTLigand Pharmaceuticals (Nasdaq: LGND) to resume trading at 9:45AM ET following FDA approval for PROMACTA... More
Ligand (LGND), Glaxo (GSK) Receive FDA Approval for PROMACTA in HCV Patients
November 19, 2012 9:11 AM ESTLigand Pharmaceuticals (Nasdaq: LGND) partner GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to... More
